Royal Marsden Reports on its Participation in the Significant Checkmate 067 Trial: Survival now Extended for Advanced Melanoma Patients

A new treatment based on combining two drugs—nivolumab and ipilimumab—may represent a milestone in how we treat skin cancer patients. More than half of these patients can now survive the condition (considered untreatable just a decade ago) thanks to a study led by the Royal Marsden NHS Foundation Trust found. This major milestone means that more lives with those struggling with advanced melanoma can be saved immediately.
A decade ago, only half of skin cancer patients survived melanoma with many dying within months of diagnosis.  Moreover, about 1 in every 20 patient with advanced melanoma survived a decade ago. With the latest study results from the Royal Marsden, new hope for advanced melanoma patients is at hand when combining  Bristol-Myers Squibb’s nivolumab (Opdivo) and ipilimumab (Yervoy).
The Checkmate 067 Trial
The Checkmate 067 trial occurred from 2013 and runs through 2021—it is sponsored by American pharmaceutical company Bristol-Myers Squib. It involved over 140 clinical investigational sites, including Royal Marsden NHS Foundation Trust. The trial saw 945 patients with advanced melanoma randomized into three groups including: 1) 314 patients receive...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee